ALZAMEND NEURO, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
ALZAMEND NEURO, INC. (ALZN) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$8.77 million for the 12-month period ending 2026-04-30, per its 10-K filed 2026-07-22.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-07-22
- ALZAMEND NEURO, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2026 was -$8.77M.
- ALZAMEND NEURO, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$4.51M.
- ALZAMEND NEURO, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$9.95M.
- ALZAMEND NEURO, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$14.88M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2026-04-30 | -$8.77M 10-K · filed 2026-07-22 |
| 2025-04-30 | -$4.51M 10-K · filed 2026-07-22 |
| 2024-04-30 | -$9.95M 10-K · filed 2025-07-22 |
| 2023-04-30 | -$14.88M 10-K · filed 2024-07-30 |
| 2022-04-30 | -$12.36M 10-K · filed 2023-07-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |